Sun, Dec 28, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Abenomics and its effect on the Japanese equity market hits all the right notes for ING Investment Management

Wednesday, April 24, 2013

By Beverly Chandler, Opalesque London:

Patrick Moonen, Senior Equity Strategist at ING Investment Management reports that the Japanese equity market is one of the firm’s most preferred markets. "Japan now has the best chance in more than a decade to leave the deflationary environment it has been in" he explains. "It is sustainable to continue with the loose monetary policy without limits until inflation reaches 2% - the Bank of Japan can continue buying Japanese government bonds."

It’s not just the loose monetary policy but also relative earnings momentum in Japan that appeals to ING. Earnings momentum is at its highest level in almost three years whereas in the US, Europe and the emerging markets, earnings momentum continues to be negative. "This is a powerful factor behind the performance of Japanese equities" Moonen says.

The depreciation of the yen to an average of 95 against the dollar has encouraged earnings growth of over 40% to March 2014 and forward valuations that make Japan as cheap as Europe. "But here the Japanese central bank is more flexible than the ECB" Moonen comments.

The third element and consequence of Abenomics is that Japan is really getting the benefit of the doubt that economic growth figures will pick up later this year and into 2014, Moonen says. "These factors differentiate between the regions and Japan scores relatively highly on each of these factors."

In addition, Moon......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its